A Canadian Collaboration
Highlights from CLCCO and Beyond
Table of Contents
- Presentation Summaries
- Canadian Perspective
An Interview with Dr. Arik Drucker on the Treatment of Non-Small Cell Lung Cancer in Canada
Is the PD-L1 Biomarker Needed in Squamous Cell Carcinoma of the Lung? A Summary of the Debate between Dr. Normand Blais and Dr. Charles Butts at CLCCO 2016
- Canadian Perspective
Institution Spotlight Mutation Testing: An Interview with Dr. Simon Raphael
Normand Blais, MD, MSc, FRCPC
After completing his medical degree at the Université de Sherbrooke in 1990, Dr. Blais trained in Internal Medicine, Hematology and Medical Oncology at the Université de Montréal. Thereafter, he took a year’s sabbatical to receive specialized training at McMaster University where he completed a master’s degree in Physiology. He currently practises at the Centre hospitalier de l’Université de Montréal (CHUM) Cancer Centre, where he is Chair of the Thoracic Oncology program and Director of both the fellowship program and clinical research unit in Thoracic Oncology. He also serves on the Genitourinary Oncology team.
Dr. Blais has been the vice-president and webmaster of GEOQ, the Oncology Task Force of Quebec (Groupe d’étude en oncologie du Québec, www.geoq.info), since its creation in 1998. He participated as an organizer and speaker in several of the workshops sponsored by GEOQ, as well as in many other continuing medical education events. He is principal investigator of many studies related to lung cancer, cancer of the pleura, and bladder cancer. Dr. Blais holds a position as Associate Professor in the Faculty of Medicine at the Université de Montréal.
Charles A. Butts, MD, FRCPC
Dr. Charles A. Butts is a Medical Oncologist at the Cross Cancer Institute and Professor of Oncology at the University of Alberta, Edmonton, Alberta, Canada. His main clinical and research interests are in the area of Thoracic Oncology. He graduated from medical school at Dalhousie University and subsequently completed training in Internal Medicine and Medical Oncology at the University of Ottawa and the Ottawa Regional Cancer Centre. He served as the Residency Program Director in Medical Oncology at the Cross Cancer Institute and University of Alberta from 2000 to 2006. From 2007 to 2014, he was Medical Director of the Community Oncology Program for the Alberta Cancer Program and subsequently Cancer Control Alberta. Dr. Butts has also served as President of the Canadian Association of Medical Oncologists. He is currently a member of the National Cancer Institute of Canada – Clinical Trials Group Lung Executive Committee and the Health Canada Scientific Advisory Committee on Oncology Therapies.
Filippo de Marinis, MD
Dr. Filippo de Marinis has been the Director of the Division of Thoracic Oncology at the European Institute of Oncology (IEO) in Milan, Italy, since November 2013. He earned his medical degree in 1978 from La Sapienza University in Rome, followed by a dual specialization in Lung Diseases (La Sapienza University) and Medical Oncology (La Cattolica University in Rome).
From 1987 to 1991, Dr. de Marinis has been a Member of the Board of Directors of the Medical Hospital School in Rome and from 2007 to 2013 he became an Adjunct Professor in Thoracic Oncology at the Biomedical Campus University of Rome and La Sapienza University. Between 2000 and 2013, Dr. de Marinis was the Director of the First Oncological Pulmonary Division at San Camillo Hospital in Rome. He was a founding Member of the Italian Association of Thoracic Oncology (AIOT) and became its first President in 2007, a post he held for five years.
Dr. de Marinis has been Associate Editor for the Lung Cancer journal from 2011 to 2013. He has published over 170 original papers in international indexed reviews and 14 books/monographers on Thoracic Oncology. Dr. de Marinis is an Expert in Good Clinical Practice Trials on New Antineoplastic Drugs in Lung Cancer (phase II/III).
Arik Drucker, MD, FRCPC
Dr. Drucker is a Medical Oncologist and Associate Professor at the Queen Elizabeth II Health Sciences Centre and Dalhousie University Faculty of Medicine in Halifax. His clinical practice focuses on the treatment of thoracic and breast cancer patients. Dr. Drucker’s interests include research in selective biomarkers; he has previously received grants from the Canadian Breast Cancer Foundation and his current project includes a concordance study of cfDNA in non-small cell lung cancer tumour and plasma specimens.
Peter Ellis, MBBS, MMed, PhD, FRACP, FRCPC
Dr. Peter Ellis is a Professor in the Departments of Oncology and Clinical Epidemiology & Biostatistics at McMaster University. He is also Division Head of Medical Oncology at the Juravinski Cancer Centre (JCC). He obtained his medical degree at the University of Sydney. He completed a Masters of Medicine (Clinical Epidemiology) and a PhD, also at the University of Sydney. Dr. Ellis moved to Canada in October, 2000. He is currently Chair of the JCC Lung Disease Site Team, an Executive Member of the National Cancer Institute of Canada (NCIC) Clinical Trials Group Lung Disease Site Committee, and Co-Chair of Cancer Care Ontario’s Practice Guideline Initiative, Provincial Lung Disease Site Group. He is also an investigator on several NCIC and pharmaceutical industry-sponsored multicentre phase III clinical trials in breast and lung cancer.
Simon Raphael, MD, MEd, FRCPC
Dr. Simon Raphael obtained his medical degree at the University of Western Ontario, where he also completed his specialty training in Anatomical Pathology. He practised medicine and was a faculty member at the University of Western Ontario for 10 years.
Dr. Raphael obtained a position at Sunnybrook Health Sciences Centre and the University of Toronto in 2000. In 2004, he completed his masters of education at the University of Toronto. Dr. Raphael was in charge of Pulmonary Pathology at Sunnybrook Health Sciences Centre and the Odette Cancer Centre for 13 years. During this time, he developed an interest in the pathologists’ role in personalized medicine for Pulmonary Oncology. He worked closely with his clinical colleagues to develop unique and innovative ways to make molecular pathology information readily available.
Since 2013, he has been the Chief of Pathology at North York General Hospital, and has held a faculty appointment as an Associate Professor at the University of Toronto. During this time, he has brought his interest and expertise in delivering personalized medicine in oncology to the wider community.
Denis Soulières, MD, MSc, FRCPC
Dr. Denis Soulières is a Hemato-oncologist and Director of the Special Hematology and Molecular Biology Laboratory at the Centre hospitalier de l’Université de Montréal (CHUM). He is also an Associate Professor at the Université de Montréal. He obtained his medical degree at Université Laval and then trained in Pediatrics, Pediatric and Adult Hematology, and Pediatric and Adult Medical Oncology at the Université de Montréal. He also completed postdoctoral training in clinical development in Switzerland and the United States. His research interests include predictive and prognostic factors in head and neck cancers, Pulmonary Oncology, and Urologic Oncology. In addition, he is interested in the standardization of diagnostic tests in oncology. Dr. Soulières has been involved in clinical trials in non-small cell lung cancer, head and neck cancer, and renal cancer.